Having trouble accessing articles? Reset your cache.

Oct. 30 Company Quick Takes: Clinical hold for Zolgensma; plus Biogen-Alkermes, Roche’s satralizumab, Pear-Ironwood

Partial hold for Novartis’ SMA gene therapy
FDA placed a partial clinical hold on studies of intrathecally delivered Zolgensma onasemnogene abeparvovec-xioi from Novartis AG (NYSE:NVS; SIX:NOVN) to treat spinal muscular atrophy

Read the full 306 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers